Lisa A. Jackson, MD, MPH

Jackson_Lisa_A__205x293.jpg

“Kaiser Permanente Washington gives us nearly unlimited potential to address vaccine effectiveness and safety questions of national and international importance.”

Lisa A. Jackson, MD, MPH

Senior Investigator, Kaiser Permanente Washington Health Research Institute
Physician, Washington Permanente Medical Group, Internal Medicine

Biography

Lisa A. Jackson, MD, MPH, is an internist and infectious disease epidemiologist who has conducted clinical and epidemiologic studies of vaccine safety and efficacy since 1991.

Dr. Jackson is the principal investigator (PI) of KPWHRI’s Vaccine and Treatment Evaluation Unit — one of 10 network sites that the National Institutes of Health (NIH) sponsors. In this role, she leads the phase 1 clinical trial of the COVID-19 vaccine co-developed by Moderna and NIH. Launched in March 2020, this trial was the first in the world to begin testing a COVID-19 vaccine. She is also leading the phase 3 clinical trials of the COVID-19 vaccines developed by Moderna and NIH and by Janssen Pharmaceutical Companies, part of Johnson & Johnson, at KPWHRI.

Additionally, Dr. Jackson serves as KPWHRI’s principal investigator in the Vaccine Safety Datalink Project (VSDP). Sponsored by the Centers for Disease Control and Prevention (CDC), VSDP conducts ongoing research on the safety of licensed vaccines in routine use.

Dr. Jackson has written more than 200 peer-reviewed publications and 14 book chapters. She is a past member of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee and the National Vaccine Program Office’s National Vaccine Advisory Committee.

After receiving her medical degree from the University of Virginia School of Medicine, in Charlottesville, Dr. Jackson earned her Master of Public Health (MPH) degree at the University of Washington (UW) School of Public Health. She completed her internal medicine residency training at the UW School of Medicine and served as an epidemic intelligence officer and preventive medicine resident at the CDC.

Research interests and experience

Vaccines & Infectious Diseases

Vaccine  safety; COVID-19 vaccine safety and effectiveness; influenza vaccine effectiveness in the elderly; methodologic issues in  vaccine effectiveness evaluations; pneumococcal polysaccharide vaccine  effectiveness; pneumococcal conjugate vaccine immunogenicity in the elderly;  epidemiology of E. coli bacteremia; epidemiology of community-acquired  pneumonia

Recent publications

Zerbo O, Modaressi S, Goddard K, Lewis E, Getahun D, Palmsten KK, Fuller CC, Crane B, Donahue JG, Daley MF, Jackson LA, Wodi AP, McNeil MM, Klein NP. Safety of live-attenuated vaccines in children exposed to biologic response modifiers in utero. Pediatrics. 2022 Jul 1;150(1):e2021056021. doi: 10.1542/peds.2021-056021. PubMed

Lyke KE, Atmar RL, Islas CD, Posavad CM, Szydlo D, PaulChourdhury R, Deming ME, Eaton A, Jackson LA, Branche AR, El Sahly HM, Rostad CA, Martin JM, Johnston C, Rupp RE, Mulligan MJ, Brady RC, Frenck RW Jr, Bäcker M, Kottkamp AC, Babu TM, Rajakumar K, Edupuganti S, Dobrzynski D, Coler RN, Archer JI, Crandon S, Zemanek JA, Brown ER, Neuzil KM, Stephens DS, Post DJ, Nayak SU, Suthar MS, Roberts PC, Beigel JH, Montefiori DC; DMID 21-0012 Study Group. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 omicron variant. Cell Rep Med. 2022 Jul 19;3(7):100679. doi: 10.1016/j.xcrm.2022.100679. Epub 2022 Jun 20. PubMed

Chung JR, Kim SS, Flannery B, Smith ME, Dunnigan K, Raiyani C, Murthy K, Gaglani M, Jackson ML, Jackson LA, Bear T, Moehling Geffel K, Nowalk MP, Zimmerman RK, Martin ET, Lamerato L, McLean HQ, King JP, Belongia EA, Thompson MG, Patel M. Vaccine-associated attenuation of subjective severity among outpatients with influenza. Vaccine. 2022 Jul 30;40(32):4322-4327. doi: 10.1016/j.vaccine.2022.06.019. Epub 2022 Jun 14. PubMed

Zerbo O, Modaressi S, Goddard K, Lewis E, Fireman B, Daley MF, Irving SA, Jackson LA, Donahue JG, Qian L, Getahun D, DeStefano F, McNeil MM, Klein NP. Safety of measles and pertussis-containing vaccines in children with autism spectrum disorders. Vaccine. 2022 Apr 20;40(18):2568-2573. doi: 10.1016/j.vaccine.2022.03.031. Epub 2022 Mar 18. PubMed

Chung JR, Kim SS, Belongia EA, McLean HQ, King JP, Nowalk MP, Zimmerman RK, Moehling Geffel K, Martin ET, Monto AS, Lamerato LE, Gaglani M, Hoffman E, Volz M, Jackson ML, Jackson LA, Patel MM, Flannery B. Vaccine effectiveness against COVID-19 among symptomatic persons aged =12?years with reported contact with COVID-19 cases, February-September 2021. Influenza Other Respir Viruses. 2022 Feb 15. doi: 10.1111/irv.12973. Online ahead of print. PubMed

Irving SA, Groom HC, Dandamudi P, Daley MF, Donahue JG, Gee J, Hechter R, Jackson LA, Klein NP, Liles E, Myers TR, Stokley S. A decade of data: adolescent vaccination in the vaccine safety datalink, 2007 through 2016. Vaccine. 2022 Feb 23;40(9):1246-1252. doi: 10.1016/j.vaccine.2022.01.051. Epub 2022 Feb 4. PubMed

Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, Rostad CA, Martin JM, Johnston C, Rupp RE, Mulligan MJ, Brady RC, Frenck RW Jr, Bäcker M, Kottkamp AC, Babu TM, Rajakumar K, Edupuganti S, Dobrzynski D, Coler RN, Posavad CM, Archer JI, Crandon S, Nayak SU, Szydlo D, Zemanek JA, Dominguez Islas CP, Brown ER, Suthar MS, McElrath MJ, McDermott AB, O'Connell SE, Montefiori DC, Eaton A, Neuzil KM, Stephens DS, Roberts PC, Beigel JH; DMID 21-0012 Study Group. Homologous and heterologous Covid-19 booster vaccinations. N Engl J Med. 2022 Jan 26. doi: 10.1056/NEJMoa2116414. Online ahead of print. PubMed

Glanz JM, Clarke CL, Daley MF, Shoup JA, Hambidge SJ, Williams JTB, Groom HC, Kharbanda EO, Klein NP, Jackson LA, Lewin BJ, McClure DL, Xu S, DeStefano F. The childhood vaccination schedule and the lack of association with type 1 diabetes. Pediatrics. 2021 Dec 1;148(6):e2021051910. doi: 10.1542/peds.2021-051910. PubMed

Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, Rostad CA, Martin JM, Johnston C, Rupp RE, Mulligan MJ, Brady RC, Frenck RW, Bäcker M, Kottkamp AC, Babu TM, Rajakumar K, Edupuganti S, Dobryzynski D, Posavad CM, Archer JI, Crandon S, Nayak SU, Szydlo D, Zemanek J, Islas CPD, Brown ER, Suthar MS, McElrath MJ, McDermott AB, O'Connell SE, Montefiori DC, Eaton A, Neuzil KM, Stephens DS, Roberts PC, Beigel JH; DMID 21-0012 Study Group. Heterologous SARS-CoV-2 booster vaccinations - preliminary report. medRxiv. 2021:2021.10.10.21264827. doi: 10.1101/2021.10.10.21264827. Preprint. PubMed

El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, Campbell TB, Clark J, Jackson LA, Fichtenbaum CJ, Zervos M, Rankin B, Eder F, Feldman G, Kennelly C, Han-Conrad L, Levin M, Neuzil KM, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Polakowski L, Mascola JR, Ledgerwood JE, Graham BS, August A, Clouting H, Deng W, Han S, Leav B, Manzo D, Pajon R, Schödel F, Tomassini JE, Zhou H, Miller J; COVE Study Group. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med. 2021 Sep 22. doi: 10.1056/NEJMoa2113017. Online ahead of print. PubMed

 

New findings

Mix-and-Match-COVID-vaccine-trial_1col.jpg

Updated results from COVID-19 vaccine booster trial

IDCRC study finds rapid decline in vaccine-boosted neutralizing antibodies against Omicron variant BA.5

Recruiting volunteers

SchistoShield-1col.jpg

Researchers begin clinical trial to assess schistosomiasis vaccine

Participant in KPWHRI trial has first-ever injection of SchistoShield vaccination.

New clinical trial

Hand with rubber glove holding vaccine vial

NIAID-sponsored study evaluates second COVID-19 booster shots

KPWHRI joins trial that includes multiple variant vaccines.

KPWHRI In the Media

Seattle-based clinical trial tweaks mRNA vaccines to fight COVID variants

Seattle NPR affiliate KUOW-FM, April 8, 2021

Expanded trial

Vaccine-trial-vaccine-NOVAVAX-boosters_1col.jpg

Volunteers needed for COVID-19 booster trial

New arm of NIAID-sponsored mix-and-match trial will look at Novavax protein vaccine.